Fast Market Research

Now Available: Investigation Report on China Insulin Glargine Market, 2009-2018

Recently published research from CRI, "Investigation Report on China Insulin Glargine Market, 2009-2018", is now available at Fast Market Research

 

Boston, MA -- (ReleaseWire) -- 03/12/2014 -- With the improvement of people's living standard and changing of lifestyles, as well as deepening of the aging of society, prevalence rate of diabetes keeps rising, making it the third most threatening chronic disease to human health after tumor and cardiovascular disease. Its risk to disable or kill has become a heavy burden on individuals, families, society and governments.

According to statistics from IDF (International Diabetes Federation), the global prevalence rate of diabetes among adults aged 20 to 79 was 8.3% in 2013. The number of diabetes patients has reached 382 million, of which 80% are from medium- and low-income countries where it is still rising rapidly.

View Full Report Details and Table of Contents

It is estimated that by 2035 there will be nearly 592 million people worldwide suffering from diabetes. In the evaluation of diabetes incidence and its trend among various countries and regions, China ranked the first with 98.4 million diabetes patients in 2013, followed by India (65.1 million), the U.S.A. (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that the number of diabetes patients in China will reach 143 million by 2035, which will still be the highest worldwide while that in the U.S.A. will merely reach 29.7 million. Rapid growth of diabetes in China and other developing countries has become an extraordinarily serious burden for these countries' social and economic development.

Insulin glargine is the first long-acting insulin analogue produced through recombinant DNA technology. It was approved for use by FDA (Food and Drug Administration) in April 2000 and EMEA (European Medicines Evaluation Agency) in June 2000. As there is no apparent peak in long-term use of insulin glargine, it has become the most widely used insulin in the United States.

In China, the third-generation insulin is under promotion. Because of the relatively high price, it is mainly used in first-tier cities at present. The second and third generation insulin will be faced with a market pattern of dislocation competition.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2013
- Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2013
- Insulin Resistance - Pipeline Review, H1 2013
- Type 2 Diabetes - Pipeline Review, H2 2013
- Investigation Report on China Duloxetine Market, 2009-2018
- Investigation Report on China Budesonide Market, 2009-2018
- Investigation Report on China Bevacizumab Market, 2009-2018
- Investigation Report on China Montelukast Market, 2009-2018
- Investigation Report on China Enoxaparin Sodium Market, 2009-2018
- Investigation Report on China Rituximab Market, 2009-2018